Methanobrevibacter Smithii

Methanobrevibacter smithii is the dominant methanogenic archaeon in the human gut, responsible for consuming hydrogen gas produced by fermentative bacteria and converting it to methane. Despite being an archaeon rather than a bacterium, it represents 0–15% of gut microbial biomass in healthy individuals and up to 50% in some diseased states (Miller & Wolin 1982 Arch Microbiol; Dridi et al. 2009 PLoS ONE). M. smithii is strictly anaerobic and obligately methanogenic, making it a critical player in the gut ecological economy and a consistent marker in dysbiotic states associated with constipation, slow gut transit, obesity, and multiple sclerosis.

Taxonomy and Basic Properties

  • Phylum: Euryarchaeota
  • Class: Methanobacteria
  • Order: Methanobacteriales
  • Family: Methanobacteriaceae
  • Genome: ~1.8 Mb; smaller than most bacteria
  • Cell Structure: Lacks peptidoglycan; archaeal lipid bilayer (ether-linked); flagella for motility
  • Oxygen Requirement: Strict anaerobe; inhibited by O2 at concentrations >5 ppm
  • Growth Rate: Slow; doubling time ~6–12 hours

Nickel Dependency and Metal Cofactors

M. smithii has an absolute requirement for nickel to synthesize two critical metalloproteins:

NiFe-Hydrogenase

  • Uses nickel-iron clusters ([NiFe] cofactors) to oxidize H2.
  • In the gut, this enzyme scavenges hydrogen produced by fermentative bacteria (e.g., Bacteroides, Faecalibacterium) (Samuel & Gordon 2006 PNAS; [1]).
  • H2 would otherwise accumulate, creating a hostile reducing environment; methanogenesis by M. smithii converts H2 to the more storable methane.
  • Nickel deprivation eliminates hydrogenase assembly and suppressively slows methanogenesis, effectively starving M. smithii.

Methyl-Coenzyme M Reductase (Mcr)

  • The terminal enzyme in methanogenesis; uses a unique nickel-containing cofactor (Ni-F430).
  • Catalyzes the reduction of methyl-CoM to methane; this is the final energy-yielding step.
  • Requires cobalt and iron in addition to nickel for cofactor maturation pathways.

Metal Acquisition

  • M. smithii scavenges nickel, cobalt, and iron from the gut lumen via receptor-binding mechanisms.
  • No siderophores synthesized; relies on ferrous iron and nickel supplied by diet or host iron-binding proteins.
  • Elevated hepcidin (host iron-withholding defense) can suppress M. smithii by reducing bioavailable Fe and Ni.

Methanogenesis Pathway and Hydrogen Consumption

M. smithii operates the hydrogenotrophic methanogenesis pathway:

``` H2 + CO2 → CH4 ```

via sequential reduction of CO2:

  1. Formyl-MFR → Methenyl-MFR → Methylene-MFR → Methyl-CoM → Methane
  2. Each step requires redox cofactors (MFR = methanofuran; CoM = coenzyme M).
  3. The final reduction to CH4 is catalyzed by Mcr (Ni-F430).

Ecological impact: By consuming H2, M. smithii relieves acetogenic bacteria (e.g., Acetobacterium, Syntrophobacter) of thermodynamic constraint. This allows continued fermentation and SCFA production, but only if the fermentation rate stays ahead of methanogenesis.

Role in Dysbiosis and Disease

Obesity and Metabolic Dysfunction

  • Consistently enriched in obese humans across multiple cohorts (Zhang et al. 2009 PNAS; Million et al. 2012 Int J Obes).
  • Elevated methane producers correlate with constipation, slow intestinal transit, and increased energy harvest from dietary fiber (Pimentel et al. 2006 Dig Dis Sci; Samuel & Gordon 2006 PNAS).
  • Proposed mechanism: Methane slows intestinal peristalsis via enteric nervous system effects, creating a positive feedback loop (slow transit → more H2 substrate for methanogenesis → more methane → even slower transit).
  • Increased energy extraction from the same food may drive weight gain (passive caloric surplus).

Irritable Bowel Syndrome (IBS)

  • Enriched in constipation-predominant IBS (IBS-C) and normal-transit IBS (Pimentel et al. 2003 Am J Gastroenterol; Kim et al. 2012 J Clin Gastroenterol).
  • Elevated fecal methane is a diagnostic biomarker for IBS-C (Pimentel et al. 2006 Dig Dis Sci).
  • Methane causes bloating, distention, and altered gut motility.

Multiple Sclerosis (MS)

  • Enriched in MS patients; associated with altered gut barrier function and increased LPS translocation ([2]; [3]).
  • May contribute to Th17 polarization via altered short-chain fatty acid (SCFA) production (if its H2 consumption reduces acetogenic efficiency) ([4]).
  • Linked to constipation and GI dysfunction common in MS ([5]).

Cardiovascular Disease (CVD)

  • Elevated methanogens associated with altered lipid metabolism and increased bile acid deconjugation (synergy with collinsella).
  • Methane slows transit → prolonged bile acid reabsorption → altered lipid homeostasis.

Interplay with Fermentative Bacteria

M. smithii depends on other bacteria for its substrate (H2). Key H2-producing taxa:

TaxonPrimary FermentationH2 Yield
bacteroides fragilisStarch/pectin → acetate + propionateLow
faecalibacterium prausnitziiCarbohydrates → butyrateHigh
prevotella sppPectin, mucin → acetateMedium
Clostridium (cluster IV)Plant polysaccharides → butyrate + H2High

When H2-producing taxa are depleted, M. smithii starves. This creates an intervention strategy: suppress fermenters OR restrict nickel supply.

Ecological Transitions and Biofilm Formation

  • M. smithii does not form biofilms alone but integrates into mixed anaerobic biofilms with bacteria and fungi.
  • In slow-transit dysbiosis (constipation, megacolon), M. smithii aggregates densely with bacteroides, prevotella, and clostridium spp.
  • Reduced peristalsis creates anaerobic microenvironments (lower pO2, more stratified layers), favoring methanogen abundance.
  • This is distinct from acute dysbiosis (e.g., C. difficile overgrowth), where M. smithii may be secondary to pathogenic dominance.

Detection and Quantification

Molecular Methods

  • 16S rRNA gene sequencing: Primers targeting archaeal 16S (e.g., ARC344F/ARC915R) distinguish M. smithii from bacterial 16S.
  • Quantitative PCR (qPCR): Genus- or species-specific primers; typical range in healthy gut: 10^6–10^8 copies/g feces.
  • Shotgun metagenomics: M. smithii genome is well-characterized; read abundance correlates with species-level quantification.
  • Note: Standard bacterial 16S primers often miss archaea; archaeal-specific sequencing required.

Functional Assays

  • Methane breath test (MBT): Exhaled methane >20 ppm in breath indicates active methanogenesis; correlates with constipation and M. smithii abundance.
  • FISH (fluorescence in situ hybridization): Archaea-specific probes (e.g., ARCH915) visualize M. smithii in fecal samples.
  • Anaerobic culture: Requires H2 atmosphere and CO2; slow-growing; mainly research setting.

Typical Abundance Ranges

PopulationM. smithii (% of microbiota)Notes
Healthy adults (non-methanogens)~10–15%Varies widely; some individuals have <1% (Dridi et al. 2009 PLoS ONE)
Healthy adults (methanogens)30–50%In CH4-producing individuals (Miller & Wolin 1982 Arch Microbiol)
Obese individuals15–30%Enriched vs lean controls (Zhang et al. 2009 PNAS; Million et al. 2012 Int J Obes)
IBS-C patients20–40%Often elevated; correlates with methane breath test (Pimentel et al. 2006 Dig Dis Sci)
MS patients (GI dysfunction)20–35%Enriched; associated with constipation ([2])

Connections to WikiBiome Entities and Disease Signatures

  • – Primary substrate; M. smithii is the major consumer in healthy gut
  • short chain fatty acids – Indirectly; SCFA-producing bacteria supply H2
  • – Product; atmospheric methane and enteric emissions from ruminants also involve M. smithii-like methanogens
  • nickel – Absolute requirement; low dietary/bioavailable nickel suppresses M. smithii
  • iron – Co-required for cofactor maturation; elevated hepcidin suppresses M. smithii
  • cobalt – Required for Mcr maturation
  • multiple sclerosis – Enriched in MS; associated with GI dysfunction and altered SCFA production
  • obesity – Consistently enriched in obese vs lean individuals
  • – Methane slows transit; methanogen enrichment is a biomarker for slow-transit IBS
  • – Enriched in IBS-C; methane breath test is diagnostic
  • cardiovascular disease – Indirect via altered bile acid reabsorption and lipid metabolism
  • dysbiosis – Enrichment signals altered hydrogen cycling and ecological dysfunction

<!— Intervention/practitioner content moved to Cureva per public/clinical boundary —>

—-

Note: Methanobrevibacter smithii remains the only archaeon yet discovered to be universally present and functionally dominant in the human microbiome.

References (7)

  1. . abdel azim 2018 heavy metals vfas methanococcus
  2. . jangi 2016 gut microbiome alterations ms
  3. . thirion 2023 gut microbiota ms disease activity
  4. . bronzini 2023 feeding gut microbiome ms
  5. . mirza 2024 mediterranean diet pediatric ms microbiota
  6. . rashed 2022 manipulation gut microbiota crohns
  7. . krawczyk 2025 fmt fungal archaeal species rat schizophrenia model

Related Articles